Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	Adults with chronic non-malignant pain based in primary, secondary, and tertiary care 2 RCTs in this analysis	Total number of adverse effects with naloxone with placebo Absolute results not reported	RR 1.13 95% CI 0.97 to 1.32		Not significant
RCT	185 adults with moderate to severe cancer pain	Proportion of people with adverse effects (any) 79/92 (86%) with PR oxycodone/naloxone plus PR oxycodone placebo 71/92 (77%) with PR oxycodone plus PR oxycodone/naloxone placebo	Significance not reported
RCT	185 adults with moderate to severe cancer pain	Total number of adverse effects related to study medication as assessed by the study investigator 77 with PR oxycodone/naloxone plus PR oxycodone placebo 62 with PR oxycodone plus PR oxycodone/naloxone placebo	Significance not reported